Bendell, Johanna C.
Bischoff, Helge G.
Hwang, Jimmy
Reinhardt, Hans Christian
Zander, Thomas
Wang, Xuejing
Hynes, Scott
Pitou, Celine
Campbell, Robert
Iversen, Philip
Farrington, Daphne L.
Bell-McGuinn, Katherine
Thomas, Michael
Funding for this research was provided by:
Eli Lilly and Company (N/A)
Article History
Received: 9 August 2019
Accepted: 22 October 2019
First Online: 9 November 2019
Compliance with ethical standards
:
: Dr. Bendell reports the following: grants (payment to institution for conduct of clinical trials for which Dr. Bendell served as PI) from EMD Serono, Koltan, SynDevRex, Forty Seven, Abbvie, Onyx, Takeda, Eisai, CellDex, Cytomx, Nektar, Boston Biomedical, Tarveda, Tyrogenex, Marshall Edwards, Pieris, Pfizer, Mersana, Calithera, Blueprint, Evelo, Merus, Jacobio, Effector, Novocare, Arrys, tracon, Sierra, Unum Therapeutics, Vyriad, Harpoon, Acerta Pharma, Rgenix, Millennium, ImClone, ADC, and Bellicum; grants and consulting services (payment to institution for conduct of clinical trials for which Dr. Bendell served as PI, and payment to institution for consulting services by Dr. Bendell) from Gilead, Genentech/Roche, Bristol Myers Squibb, Five prime, Eli Lilly, Merck, MedImmune, Celgene, Taiho, Marcogenics, GSK, Novartis, OncMed, LEAP, TG Therapeutics, Astra Zeneca, BI, Bayer, Apexgen, Array, Prelude Oncology, Sanofi, Agios, ARMO, Ispen, Merrimack, Oncogenex, FORMA, Innate, Arch Oncology, and Amgen; consulting services (payment to institution for consulting services by Dr. Bendell) from Phoenix Bio, Cyteir, Molecular Partners, Torque, Tizona, Translational Drug Development, Seattle Genetics, Moderna Therapeutics, Tanabe Research Laboratories, Beigene, and Continuum Clinical.Dr. Bischoff has nothing to disclose.Dr. Hwang has nothing to disclose.Dr. Reinhardt has nothing to disclose.Dr. Zander reports serving on advisory boards from Roche, BMS, MSD, Novartis, Pfizer, and Eli Lilly.Dr. Bell-McGuinn, Dr. Campbell, and Dr. Wang are employees and shareholders of Eli Lilly.Dr. Hynes, Dr. Iversen, Dr. Pitou are employees of Eli Lilly.D. Farrington is an employee and shareholder of Verastem Oncology, and reports personal fees and is a shareholder of Eli Lilly, and is a shareholder of Sesen Bio Inc.Dr. Thomas reports personal fees from AbbVie, grants, personal fees and non-financial support from Bristol-Myers Squibb, personal fees and non-financial support from Boehringer Ingelheim, personal fees from Lilly, personal fees and non-financial support from MSD, personal fees and non-financial support from Novartis, grants and personal fees from Roche, and grants from AstraZeneca, during the conduct of the study.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. The study was registered at ExternalRef removed as NCT02860780. Informed consent was obtained from all individual participants included in the study.
: Informed consent was obtained from all individual participants included in the study.